Emmprin expression predicts response and survival following cisplatin containing chemotherapy for bladder cancer: A validation study

Journal of Urology

Volumn 194, Issue 6, 2015, Pages 1575-1581

  Hemdan, Tammer ^a,b   Malmström, Per Uno ^a,b   Jahnson, Staffan ^a,b   Segersten, Ulrika ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

antigens; biological markers; CD147; cystectomy; drug therapy; urinary bladder neoplasms

Indexed keywords

CD147 ANTIGEN; CISPLATIN; DOXORUBICIN; METHOTREXATE; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT RESPONSE; VALIDATION STUDY; ADJUVANT THERAPY; AGED; BLADDER; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; URINARY BLADDER NEOPLASMS;

AGED; ANTIGENS, CD147; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MALE; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84947230630     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.06.085     Document Type: Article

References (15)

1. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927
2. A. Sherif, L. Holmberg, E. Rintala, and et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 2004 297
3. M. Burger, P. Mulders, and W. Witjes Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centers: results of a feasibility questionnaire Eur Urol 61 2012 1070
4. A.B. Als, L. Dyrskjøt, H. von der Maase, and et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer Clin Cancer Res 13 2007 4407
5. H.B. Grossman, C.M. Tangen, C. Cordon-Cardo, and et al. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study Oncol Rep 16 2006 807
6. V. Margulis, Y. Lotan, P.I. Karakiewicz, and et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer J Natl Cancer Inst 101 2009 114
7. M.U. Segersten, E.K. Edlund, P. Micke, and et al. A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer BJU Int 104 2009 1780
8. W.D. Zhong, Q.B. Chen, Y.K. Ye, and et al. Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer Cancer Epidemiol 34 2010 478
9. J.W. Choi, Y. Kim, J.H. Lee, and Y.S. Kim Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder Urology 84 2014 245
10. M.J. Kang, H.P. Kim, K.S. Lee, and et al. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells Proteomics 13 2013 1714
11. J. Afonso, L.L. Santos, V. Miranda-Gonçalves, and et al. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance Mol Carcinog 2014 Epub before print
12. N. Fristrup, B.P. Ulhøi, K. Birkenkamp-Demtröder, and et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer Am J Pathol 180 2012 1824
13. L.M. McShane, and D.F. Hayes Publication of tumor marker research results: the necessity for complete and transparent reporting J Clin Oncol 30 2012 4223
14. S. Gudjónsson, P.O. Bendahl, G. Chebil, and et al. Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol 45 2011 270
15. D.G. Altman Practical Statistics for Medical Research 1991 Chapman and Hall London, United Kingdom